GC
ENZN

Guggenheim Capital’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Guggenheim Capital’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-15,794
Closed -$16K – 3231
2014
Q2 		$16K Sell
15,794
-12,516
-44% -$11.9K ﹤0.01% 3172
2014
Q1 		$29K Buy
28,310
+4,355
+18% +$4.5K ﹤0.01% 3201
2013
Q4 		$28K Buy
23,955
+3,026
+14% +$4.66K ﹤0.01% 3106
2013
Q3 		$35K Buy
+20,929
New +$38.7K ﹤0.01% 2979

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Guggenheim Capital's ENZN Position: Q3 2014 in Review

Guggenheim Capital sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q3 2014, closing a stake of 15,794 shares — an estimated $16K sold.

Guggenheim Capital first reported a position in ENZN in Q3 2013 and held it in 4 quarters. The position peaked at $35K in Q3 2013. 65 funds tracked by Wall St. Rank hold ENZN as of Q3 2014.

  • Guggenheim Capital reported no remaining ENZON PHARMACEUTICALS INC position as of Q3 2014 after selling out during the quarter.
  • Guggenheim Capital sold 15,794 ENZON PHARMACEUTICALS INC shares in Q3 2014, an estimated $16K.
  • Guggenheim Capital first reported a position in ENZON PHARMACEUTICALS INC in Q3 2013 and held it in 4 quarters.
  • Guggenheim Capital's ENZON PHARMACEUTICALS INC position peaked at $35K in Q3 2013.
  • 65 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q3 2014.

Based on Guggenheim Capital's 13F filing for Q3 2014, filed 14 Nov 2014.